• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Cord colitis syndrome found to have a novel infectious etiology

bys25qthea
August 8, 2013
in Chronic Disease, Infectious Disease, Oncology
Reading Time: 3 mins read
Cord colitis syndrome found to have a novel infectious etiology
Share on FacebookShare on TwitterShare on LinkedIn

Image: PD 

1. The genome of a novel bacterium Bradyrhizobium enterica was discovered via gene sequencing in patients with cord colitis. 

2. The association of this bacterium with cord colitis suggests it may be an opportunistic pathogen of humans. 

Study Rundown:  Hematopoietic stem-cell transplantation (HSCT) is a modern procedure used to treat various hematologic and oncologic diseases by repopulating a patient’s immune system by using the cells of a donor.  HSCT requires complete suppression and even destruction of the host’s immune system and therefore may cause many adverse events including graft versus host disease (GVHD) and unusual opportunistic infections.  Colitis is a common adverse effect of HSCT and is thought to stem from various etiologies including bacterial, viral and parasitic infections, as well as GVHD.  Cord colitis is a syndrome specific to patients who have undergone umbilical-cord HSCT and is histopathologically distinct from other forms of colitis.  Additionally, conventional infectious work ups fail to reveal a known infectious pathogen in this disease. 

The authors of this study found that treating cord colitis patients with antibiotics resulted in the resolution of symptoms.  They then performed a sequencing study that identified what appears to be an opportunistic pathogen as the etiology of the disease.  The fact that B. enterica was found in the cord colitis patients and in no controls would suggest it is associated with the syndrome.  However, the overall number of patients with cord colitis who were tested was very small and from a single center.  Additionally, while not a requirement to prove disease causation, the organism was never cultured by the authors.  Demonstrating a change in DNA copy numbers after antibiotic treatment might help fulfill the modern adaptation of Koch’s postulates.  Taken together the results display an impressive demonstration of modern gene sequencing to identify a novel bacterial genome that might be an opportunistic human pathogen.

Click to read the study, published today in NEJM

RELATED REPORTS

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

Daraxonrasib extends survival in metastatic pancreatic cancer

Background Reading: A reconsideration of Koch’s Postulates

In-Depth [genome sequencing case control study]: The authors of this study selected patients from Brigham and Women’s Hospital who had developed cord colitis after receiving an umbilical cord hematopoietic stem-cell transplant.  Using archived, paraffin-embedded colon biopsy specimens, they performed mass DNA sequencing and subtracted known human and microbial sequences.  The remaining sequences were assembled into a draft genome that was homologous to known bacteria of the bradyrhizobium genus and subsequently dubbed Bradyrhizobium enterica.  They then used polymerase chain reaction (PCR) to identify this genome in 3 additional patients with cord colitis, but found it was not present in patients selected as controls.

By Akira Shishido, MD and Mitalee Patil

More from this author: Pneumocystis linked to sudden infant deaths, Continuous infusion of beta-lactams may be superior to bolus therapy, Novel antiviral drug reduces influenza viral load, Three months of antibiotics appear to effectively treat early-onset spinal implant infections 

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: Bradyrhizobium entericacord colitisgraft versus hostGVFDHematopoietic stem-cell transplantationHSCToncology
Previous Post

High glucose levels associated with increased risk of dementia

Next Post

Probiotic formulations do not prevent antibiotic-associated diarrhea

RelatedReports

A liver illustration with spilled sugar cubes and two drink cups, highlighting the link between sugary drinks and liver health.
Chronic Disease

Male sex is associated with higher mortality among patients with hepatocellular carcinoma

October 7, 2026
The image features a woman examining samples under a microscope, representations of cancer cells, a knee joint, and a liver with a pill at the center, suggesting a focus on oncology and pharmaceutical therapy.
Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

September 7, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Next Post
Probiotic formulations do not prevent antibiotic-associated diarrhea

Probiotic formulations do not prevent antibiotic-associated diarrhea

A new biomarker for therapy-resistant graft-versus-host disease and death

A new biomarker for therapy-resistant graft-versus-host disease and death

Outreach increases colorectal cancer screening among underserved

Outreach increases colorectal cancer screening among underserved

✦ EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • WGS Oncodetect showed higher recurrence sensitivity than WES Oncodetect in colorectal cancer
  • Stool biomarkers may be effective in the evaluation of necrotizing enterocolitis in preterm infants
  • Tarlatamab plus durvalumab improved survival versus durvalumab alone in extensive-stage small cell lung cancer in interim phase 3 results
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.